Diagnosis and evaluation of prognosis of myelofibrosis: a British Society for Haematology Guideline

Diagnosis and evaluation of prognosis of myelofibrosis: a British Society for Haematology Guideline

This document represents an update of the British Society for Haematology (BSH) guideline on myelofibrosis (MF) first published in 2012 and updated in 2015.1 This guideline aims to provide healthcare professionals with clear guidance on the diagnosis and prognostic evaluation of primary myelofibrosi...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	McLornan, DP, Godfrey, AL, Green, A, Frewin, R, Arami, S, Brady, J, Butt, NM, Cargo, C, Ewing, J, Francis, S, Garg, M, Harrison, C, Innes, A, Khan, A, Knapper, S, Lambert, J, Mead, A, McGregor, A, Neelakantan, P, Psaila, B, Somervaille, TCP, Woodley, C, Nangalia, J, Cross, NCP, McMullin, MF
Άλλοι συγγραφείς:	BSH Committee
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	Wiley 2023

Παρόμοια τεκμήρια

A guideline for the diagnosis and management of polycythaemia vera. A British Society for haematology guideline
ανά: McMullin, M, κ.ά.
Έκδοση: (2018)

A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis
ανά: McMullin, M, κ.ά.
Έκδοση: (2018)

Allogeneic stem cell transplantation for myelofibrosis in 2012.
ανά: McLornan, D, κ.ά.
Έκδοση: (2012)

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.
ανά: Reilly, J, κ.ά.
Έκδοση: (2014)

Guideline for the diagnosis and management of myelofibrosis.
ανά: Reilly, J, κ.ά.
Έκδοση: (2012)

Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date
ανά: Bassiony S, κ.ά.
Έκδοση: (2020-09-01)

MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic
ανά: Verstovsek, S, κ.ά.
Έκδοση: (2021)

P991: IMPAIRMENT OF TCR SIGNALLING IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB
ανά: P. Harrington, κ.ά.
Έκδοση: (2022-06-01)

A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study
ανά: Mead, AJ, κ.ά.
Έκδοση: (2022)

Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm
ανά: Salisbury, RA, κ.ά.
Έκδοση: (2021)

Allogeneic Stem Cell Transplantation for Myelofibrosis in 2012
ανά: Mclornan, D, κ.ά.
Έκδοση: (2012)

Symptomatic benefit of momelotinib in patients with myelofibrosis: results from the SIMPLIFY phase III studies
ανά: Mesa, RA, κ.ά.
Έκδοση: (2023)

Mutational spectrum defines primary and secondary myelofibrosis
ανά: Ken I. Mills, κ.ά.
Έκδοση: (2014-01-01)

Guideline for the diagnosis and management of myelofibrosis
ανά: Reilly, J, κ.ά.
Έκδοση: (2012)

Use of JAK inhibitors in the management of myelofibrosis: A revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012
ανά: Reilly, J, κ.ά.
Έκδοση: (2014)

Low-dose thalidomide in myelofibrosis
ανά: Robert Weinkove, κ.ά.
Έκδοση: (2008-07-01)

A retrospective real world evidence study to review the current treatment pathways for myelofibrosis from across the United Kingdom (the REALISM UK study)
ανά: Mead, A, κ.ά.
Έκδοση: (2019)

Guideline for the investigation and management of eosinophilia
ανά: Butt, N, κ.ά.
Έκδοση: (2017)

State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019
ανά: Donal P. McLornan, κ.ά.
Έκδοση: (2019-04-01)

Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis
ανά: Stephen T. Oh, κ.ά.
Έκδοση: (2024-02-01)

Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies
ανά: Ruben A. Mesa, κ.ά.
Έκδοση: (2023-05-01)

Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study
ανά: Ruben A. Mesa, κ.ά.
Έκδοση: (2023-11-01)

Feasibility of recruitment of patients withMyeloproliferative Neoplasms into the TAPfunded TAMARIN study
ανά: Harrison, C, κ.ά.
Έκδοση: (2018)

Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial
ανά: McIlroy, G, κ.ά.
Έκδοση: (2025)

Equivalence of BCSH and WHO diagnostic criteria for ET
ανά: Harrison, C, κ.ά.
Έκδοση: (2016)

The soldier and the post-conflict state
ανά: McMullin, J, κ.ά.
Έκδοση: (2006)

The use of genetic tests to diagnose and manage patients with myeloproliferative and myeloproliferative/myelodysplastic neoplasms, and related disorders
ανά: Cross, NCP, κ.ά.
Έκδοση: (2021)

Practical management of patients with myelofibrosis receiving ruxolitinib.
ανά: Harrison, C, κ.ά.
Έκδοση: (2013)

Ruxolitinib induces changes in histone modification status in patients entered into the MAJIC clinical trial
ανά: McPherson, S, κ.ά.
Έκδοση: (2018)

A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study
ανά: Adam J. Mead, κ.ά.
Έκδοση: (2022-03-01)

Intravesical recurrence of chromophobe renal cell carcinoma
ανά: Niall P. Kelly, κ.ά.
Έκδοση: (2023-09-01)

A single-cell approach to unraveling abnormal megakaryocyte differentiation and function in myelofibrosis
ανά: Psaila, B, κ.ά.
Έκδοση: (2017)

In utero origin of myelofibrosis presenting in adult monozygotic twins
ανά: Sousos, N, κ.ά.
Έκδοση: (2022)

Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial
ανά: Graham McIlroy, κ.ά.
Έκδοση: (2025-01-01)

P1068: RISK-ADJUSTED SAFETY ANALYSIS OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS
ανά: A. Vannucchi, κ.ά.
Έκδοση: (2022-06-01)

Spliceosome mutations are common in MPN-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide
ανά: Chowdhury, O, κ.ά.
Έκδοση: (2018)

Rapid emergence of chronic lymphocytic leukemia during JAK2 inhibitor therapy in a patient with myelofibrosis
ανά: Sousos, N, κ.ά.
Έκδοση: (2020)

Modification of the histone landscape with JAK inhibition in myeloproliferative neoplasms
ανά: Greenfield, G, κ.ά.
Έκδοση: (2020)

S197: NAVITOCLAX PLUS RUXOLITINIB IN JAK INHIBITOR-NAÏVE PATIENTS WITH MYELOFIBROSIS: PRELIMINARY SAFETY AND EFFICACY IN A MULTICENTER, OPEN-LABEL PHASE 2 STUDY
ανά: F. Passamonti, κ.ά.
Έκδοση: (2022-06-01)

The UK Myeloproliferative Neoplasm Registry for Myelofibrosis (UK-MPN-MF registry)
ανά: Butt, N, κ.ά.
Έκδοση: (2019)